Model Medicines Selected to Participate at the 5th Annual Evercore ISI HealthCONx Conference
Dr. Daniel Haders, founder and CEO of Model Medicines will be an invited presenter at the 5th Annual Evercore ISI HealthCONx Conference November 29th-December 1st.
Model Medicines’s Galileo Platform has now successfully drugged three unique areas of biology: Gastrointestinal Motility, Infectious Disease, and Oncology. The platform completed an in silico discovery program in Autoimmune and Inflammation in Q4, 2022.
In Q4, 2022, the company announced positive data and the successful launch of its Oncology Program against two “undruggable” targets - AXL & BRD4.
Model Medicines lead therapeutic, MDL-001, a best-in-class, first-in-class pan-antiviral candidate, has completed preclinical proof-of-concept testing and a pre-IND review by the FDA.
Since 2019, Model Medicines has announced more than 90+ assets for 10+ targets
LA JOLLA, CA., November 15, 2022 – Model Medicines, the pharmatech company working to transform the drug discovery and development industry and accelerate the creation of life-changing drugs using artificial intelligence (AI) and machine learning (ML), today announced that the company has been invited to participate in the 5th Annual Evercore ISI HealthCONx Conference. Model Medicines will present along with other AI-drug discovery companies like Atomwise and Exscientia, as well as larger pharma companies like Pfizer, Gilead, GSK, and AbbVie, among others.
This announcement follows recent positive data from the Company’s newly created Oncology program and previously announced Infectious Disease program. In this new program, Model Medicines identified multiple AI-discovered compounds demonstrating drug-like activity for two high value, difficult to drug, oncogenic and epigenetic targets. In Q2 of this year, Model Medicines announced that its AI-discovered lead compound, MDL-001, developed in collaboration with world-renowned researchers at Scripps Research and the Icahn School of Medicine at Mount Sinai, demonstrated preclinical proof-of-concept and first-in-class, best-in-class characteristics as a potential broad spectrum infectious disease therapeutic. Since 2019, Model Medicines has announced more than 90+ assets for 10+ targets.
Dr. Daniel Haders, founder and CEO of Model Medicines will be participating in this year’s Evercore ISI HealthCONx Conference, presenting data surrounding their four drug programs of infectious disease, oncology, gastrointestinal motility, and inflammation and rare disease.
ABOUT EVERCORE
Evercore (NYSE: EVR) is a premier global independent investment banking advisory firm. We are dedicated to helping our clients achieve superior results through trusted independent and innovative advice on matters of strategic significance to boards of directors, management teams and shareholders, including mergers and acquisitions, strategic shareholder advisory, restructurings and capital structure. Evercore also assists clients in raising public and private capital and delivers equity research and equity sales and agency trading execution, in addition to providing wealth and investment management services to high-net-worth and institutional investors. Founded in 1995, the firm is headquartered in New York and maintains offices and affiliate offices in major financial centers in North America, Europe and Asia. For more information, please visit www.evercore.com.
ABOUT MODEL MEDICINES
Model Medicines is a pharmatech company working to transform the drug discovery and development industry by accelerating the creation of life-changing drugs using artificial intelligence and machine learning. Model Medicines was started in 2019 to deliver on the promise of AI-Drug discovery. With more than 90+ assets for 10+ targets, we are delivering on the promise of AI-drug discovery. The company has developed a robust pipeline of patent-pending therapeutics for oncology, infectious diseases, gastric disorders, neurological disorders, and weight disorders. The company is based in La Jolla, CA. www.modelmedicines.com
